Results from SWORD studies prove the success of a two-drug regimen for HIV

At the 22nd International AIDS Conference (Amsterdam, Netherlands, 23–27 July 2018) ViiV Healthcare (Brentford, UK) presented results from its 100-week Phase lll trials assessing the safety and efficacy of switching virologically-suppressed individuals living with HIV from a three or four-drug antiviral regimen onto Juluca®.

Over the course of 100 weeks, the two-drug, once daily, single pill regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC) maintained viral suppression (viral load of less than 50 copies/mL) in 89% of participants.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment